IL-10-producing NKT10 subset critically prevents graft-versus-host disease in murine bone marrow transplantation
Background
Graft-versus-host disease (GVHD) remains a severe and often fatal complication following allogeneic hematopoietic stem cell transplantation (HSCT), including bone marrow transplantation (BMT). Current prophylactic and therapeutic strategies, while improving, still leave many patients vulnerable to this immune-mediated attack on recipient tissues. Invariant natural killer T (iNKT) cells are known to play a role in modulating immune responses and preventing GVHD, but the specific contributions and mechanisms of their distinct subsets, particularly the NKT10 and NKT17 populations, have been unclear. Understanding these roles is crucial for developing more targeted and effective immunotherapeutic approaches to mitigate GVHD.
Study Design
Researchers investigated the anti-GVH effects of iNKT cell subsets in a major-MHC mismatched murine BMT model. BALB/c recipients (H-2d) received grafts from C57BL/6 donors (H-2b). The graft comprised bone marrow and T cells from Traj18KO (iNKT cell deficient) mice, supplemented with iNKT cells purified from donors with various genetic alterations affecting iNKT subsets. They compared the effects of NKT17-enriched CD4- iNKT cells, NKT2-enriched CD4+ iNKT cells, NKT2/17 deficient iNKT cells, IL10KO iNKT cells, and IL17AFDKO iNKT cells on GVHD prevention. In vitro experiments using IL-17 fate-mapping mice were also conducted to assess NKT17 trans-differentiation under T regulatory type 1 (Tr1)-promoting conditions.
Results
Specific iNKT cell subsets demonstrated differential capacities to prevent GVHD. NKT17-enriched CD4- iNKT cells exhibited anti-GVH effects similar to those of NKT2-enriched CD4+ iNKT cells, suggesting both subsets contribute. In contrast, NKT2/17 deficient iNKT cells failed to prevent GVHD, highlighting the necessity of these populations. Crucially, IL10KO iNKT cells completely lost their protective effects, underscoring the indispensable role of IL-10 production by NKT10 cells in GVHD prevention. IL17AFDKO iNKT cells showed partially abrogated anti-GVH effects, further supporting the critical function of NKT10. The study also revealed that:
NKT17cells can trans-differentiate intoNKT10in vitro after antigenic stimulation underTr1-promoting conditions, suggesting a dynamic interplay between these subsets in immune regulation.
Key Findings
- NKT17-enriched CD4- iNKT cells and NKT2-enriched CD4+ iNKT cells both showed anti-GVH effects.
- NKT2/17 deficient iNKT cells failed to prevent GVHD, indicating their necessity.
- IL10KO iNKT cells completely lost their protective effects against GVHD.
- IL17AFDKO iNKT cells demonstrated partially abrogated anti-GVH effects.
- NKT17 cells can trans-differentiate into NKT10 in vitro under Tr1-promoting conditions.
Why It Matters
This research provides a critical mechanistic understanding of how specific iNKT cell subsets, particularly the IL-10-producing NKT10 cells, contribute to preventing graft-versus-host disease (GVHD) after bone marrow transplantation. For clinicians and researchers, this identifies NKT10 cells and their IL-10 production as a key therapeutic target. Strategies aimed at enhancing NKT10 cell numbers or function, or promoting the trans-differentiation of NKT17 into NKT10, could offer novel immunotherapeutic avenues to reduce GVHD severity and improve patient outcomes post-BMT. This moves beyond broad iNKT cell manipulation to a more precise, subset-specific approach, potentially leading to more effective and less toxic interventions. While currently preclinical, these findings lay the groundwork for developing cell-based therapies or pharmacological agents that modulate iNKT subset balance in human BMT settings.
nkt-cells
gvhd
bone-marrow-transplantation
immunology
il-10
il-17